Quantifying the Unfolded Protein Response with XBP1 ELISA Under ER-Stress (Tunicamycin, Thapsigargin, DTT)

Biology in 60 seconds: XBP1u vs XBP1s and IRE1α splicing

Trigger. Misfolded proteins accumulate → IRE1α dimerizes/oligomerizes → RNase domain cleaves a 26-nt intron from XBP1 mRNA.
Product. Ligation yields XBP1s, a frameshifted transcription factor with a unique C-terminus (core epitope for XBP1s-specific antibodies).
Function. XBP1s induces HSPA5/BiP, PDIs, ERAD components (e.g., EDEM1), lipid synthesis, and ER expansion. XBP1u can bind and modulate XBP1s stability and DNA binding.

Assay implication: Antibody specificity must distinguish XBP1s from XBP1u—ideally by targeting the splice junction or XBP1s-unique C-terminal region; avoid N-terminal epitopes shared by both isoforms.

Assay design: choosing and verifying the right ELISA

Formats you’ll encounter

XBP1s-specific sandwich ELISA
- Capture: monoclonal to XBP1s-unique region (junction/C-terminus).
- Detect: monoclonal/polyclonal to a non-overlapping XBP1s region.
- Best for: direct quantification of the IRE1 arm of the UPR.
Total XBP1 ELISA
- Recognizes both XBP1u and XBP1s; useful for expression kinetics but cannot isolate splicing effects without additional readouts.

Cross-reactivity safeguards

Verify vendor’s cross-reactivity ≤1–5% with XBP1u.
Run peptide competition (XBP1s-unique peptide), and blocking with XBP1u peptide to demonstrate selectivity.
Include a chemical-genetic control: pretreat with IRE1 RNase inhibitor (e.g., 4µ8C, STF-083010, MKC-3946)—XBP1s signal should drop while PERK/ATF4/CHOP may persist.

Calibrators

Use recombinant XBP1s standard; avoid calibrating with XBP1u. Check for linearity (r² ≥0.99) across your standard curve.

Experimental workflow

Cell models & treatment timelines

Common, robust lines: HEK293, HeLa, MEFs, CHO, secretory lines (e.g., HepG2, pancreatic lines) if you need strong UPR.

Tunicamycin (TM): 0.5–2 µg/mL for 6–16 h (start at 1 µg/mL/8 h). Longer incubations (≥16–24 h) raise cytotoxicity.
Thapsigargin (Tg): 50–300 nM for 4–8 h (start 100 nM/6 h). Potent; avoid >8–12 h without viability checks.
DTT: 1–3 mM for 1–6 h (start 2 mM/2–4 h). Short, strong pulses; washout optional for recovery kinetics.

Controls

Vehicle (DMSO or water) at matched % to compound stocks.
Negative pathway control: IRE1 RNase inhibitor ± stressor.
Orthogonal pathway bias: PERK inhibitor (GSK2606414) to show CHOP linkage vs XBP1s selectivity.

Lysate preparation

Buffer choice. Check kit tolerance. As a rule:
- Prefer mild lysis (e.g., 1% NP-40 or Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.5, protease/phosphatase inhibitors).
- Avoid SDS and >0.5–1% detergents unless your kit explicitly supports them. High detergents ↑ background and disrupt antibody–antigen binding.
Shear viscous lysates (25G needle) and clarify (10–15k × g, 10 min, 4 °C).
Normalize. Quantify protein (BCA compatible with detergents or DC assay), aim for 0.2–1.0 mg/mL loading equivalent per well (after any on-plate dilution).

Plate setup & run

Standards: 8–10 points (e.g., 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10 ng/mL).
Replicates: technical triplicates for standards and key samples; duplicates minimum.
Edge mitigation: Fill perimeter wells with buffer or unused sample; use plate seal; equilibrate to RT 30 min before starting.
Incubation: Follow kit times; keep timing uniform across plate to reduce drift.
Read: 450 nm (reference 570–620 nm if recommended). Verify that blank OD is within spec.

QC & performance metrics (what “good” looks like)

Metric	Target / Rule of thumb
LOD	≤ 10–50 pg/mL (blank + 3 SD)
LOQ	Within curve where CV ≤20% and recovery 80–120%
Dynamic range	~ 0.1–10 ng/mL (kit dependent)
Backfit	4PL/5PL; residuals random, r² ≥0.99
Intra-assay CV	≤10% (standards & samples)
Inter-assay CV	≤15% across days/operators
Spike recovery	80–120% in your matrix
Dilution linearity	80–120% after 1:2–1:8 serial dilutions
Edge effects	ΔOD(edge-center) <10% after mitigation

Plate effects & controls

Randomize sample positions when feasible.
Include a pooled lysate QC aliquoted across plates to trend inter-assay variation.
Maintain identical incubation times and wash rigor (incomplete washing is the #1 background driver).

Orthogonal validation & correlation analysis

XBP1 splicing RT-PCR/qPCR

Conventional RT-PCR with primers flanking the 26-nt intron yields two amplicons (XBP1u vs XBP1s) separable on 2–3% agarose.
qPCR with isoform-specific primers/probes (junction-spanning for XBP1s) provides quantitative splicing indices.
Compute Splicing Index: XBP1s / (XBP1s + XBP1u) (qPCR efficiency-corrected if needed).

Westerns

BiP/GRP78 (HSPA5): chaperone upregulated by XBP1s—should track with ELISA over longer windows (8–24 h).
CHOP (DDIT3): PERK/ATF4 branch—may increase with Tg/TM; correlation with XBP1s can decouple under RNase-inhibition.

Correlation

Acquire paired datapoints (same lysate) for ELISA XBP1s and RT-qPCR ΔCt(XBP1s) or Splicing Index; plot Pearson r/Spearman ρ; target |r| ≥0.7 with tuned windows (e.g., 6–8 h Tg, 8–16 h TM).
Include Bland–Altman if comparing ELISA to densitometric Western quantitation.

Example ER-stress study designs

A) Dose–response (single timepoint)

Cells: HEK293 at 70–80% confluence.
Treat: Tg 0, 25, 50, 100, 200, 400 nM for 6 h.
Readouts: XBP1s ELISA (primary), XBP1s RT-qPCR, BiP Western (secondary).
Outcome: EC₅₀ estimation for XBP1s induction; compare across compounds.

B) Time course (single dose)

TM: 1 µg/mL, harvest at 0, 2, 4, 8, 16, 24 h.
Parallel: IRE1 inhibitor arm (e.g., 25–50 µM STF-083010).
Outcome: Show time-dependent XBP1s accumulation, abrogation with RNase inhibitor; CHOP kinetics may diverge.

C) Compound benchmarking

Tg 100 nM 6 h, TM 1 µg/mL 12 h, DTT 2 mM 2 h.
Outcome: Distinct induction magnitudes and cytotoxicity windows; DTT often shows rapid, transient XBP1s peaks.

Troubleshooting guide

Problem	Likely cause	Fix
High background in all wells	Detergent too high; incomplete washes; plate dried between steps	Keep NP-40/Triton ≤0.5–1%; add an extra wash with soak (30–60 s); never let wells dry; ensure fresh TMB/substrate
Non-linear standards	Pipetting error; wrong curve model; edge effects	Use reverse pipetting; fit 4PL/5PL; avoid edge for standards or fill perimeter with buffer
Poor spike recovery in primary cells	Matrix effects (lipids, nucleases, binding proteins)	Serially dilute samples (1:2–1:8) into kit diluent; consider detergent-compatible blockers; validate with matrix-matched standards
Weak signal despite strong stress	Wrong antibody epitope (cross-reactive with XBP1u) or degraded antigen	Confirm junction-specific antibody; add protease inhibitors; verify treatment potency and viability
Well-to-well drift over plate	Timing differences; temperature gradients	Process columns in parallel; use multichannel; equilibrate plates/reagents to RT; maintain consistent incubation
Color interference	Phenol red, hemoglobin, lipids	Switch to phenol-red–free medium during treatment; ensure thorough washes; read with reference wavelength if available

Reporting checklist (copy into your ELN)

Cell line, passage, plating density, % confluence at dosing.
Compound identity, solvent, final solvent %, dose, exact treatment durations, media composition (phenol red ±, serum %).
Lysis buffer composition and detergent %; total protein assay type.
ELISA kit ID, lot, standard curve points, model (4PL/5PL), LOD/LOQ method.
QC: intra/inter-assay CVs, spike-recovery, dilution linearity.
Validation: primer sequences/assay IDs for XBP1s/u, antibody catalog/clone for BiP/CHOP, exposure times, quantitation method.
Statistics: biological n, technical k, correlation method, multiple-comparison correction if applicable.

Bill of materials (minimal)

Stressors: tunicamycin, thapsigargin, DTT; DMSO/water; phenol-red–free media optional.
Inhibitors (optional controls): IRE1 RNase inhibitors (4µ8C, STF-083010, MKC-3946); PERK inhibitor (GSK2606414).
ELISA: XBP1s-specific sandwich kit; compatible lysis buffer or kit diluent.
Orthogonal assays: RT-PCR/qPCR reagents (junction-spanning primers), primary antibodies to BiP and CHOP, BCA/DC protein assay.
Consumables: high-bind 96-well plates (if building in-house), plate seals, calibrated multichannel pipettes, wash bottle/automated washer.

Data interpretation tips

Compound choice changes kinetics: DTT gives rapid, short-lived XBP1s; Tg a robust mid-window; TM often slow/strong but more cytotoxic—pick timepoints accordingly.
Branch specificity: XBP1s (IRE1 arm) can rise even if CHOP (PERK arm) is modest; that divergence is informative, not an error.
Normalization strategy matters: If treatments change cell size/protein content, prefer per-cell normalization (plate-based nuclei count or DNA content) in addition to per-µg protein.

Ligand-Gated Ion Channel Database